In stock · research SKU
Retatrutide research brief
Triple GIP / GLP-1 / glucagon receptor agonist
Retatrutide 10 mg / 20 mg / 30 mg$69.99–$149.99CAD / vial
For laboratory research use only. Not for human or veterinary use, consumption, compounding into a medicine, or injection. Not authorized by Health Canada. This catalog vial is a research material, not a licensed drug.
Research-grade retatrutide for laboratory metabolic-receptor work in Canada. Triple agonist at GIP, GLP-1, and glucagon receptors. Not a licensed medicine.
Identity
Form
Lyophilized powder, sealed vial
Strength
10 mg, 20 mg, 30 mg
Purity
≥99% HPLC
CAS
- Retatrutide: 2381089-83-2
Literature
Retatrutide has been investigated in clinical research and is studied for its interaction with the GIP, GLP-1 and glucagon receptors.
- A 48-week, randomized, double-blind, placebo-controlled phase 2 trial in adults investigated once-weekly retatrutide, a GIP, GLP-1 and glucagon receptor agonist, and measured change in body weight. [1]
- A 36-week, randomized, double-blind phase 2 trial in adults with type 2 diabetes investigated once-weekly retatrutide against placebo and dulaglutide, and measured HbA1c and body weight. [2]
- The discovery paper for LY3437943 (retatrutide), describing its activity at the glucagon, GIP and GLP-1 receptors in cell assays, energy-balance endpoints in a mouse model, and pharmacokinetics in a phase 1 study. [3]
Literature is scientific context only. A paper does not make a research vial into a licensed medicine.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. PubMed 37366315 · DOI
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023. PubMed 37385280 · DOI
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022. PubMed 35985340 · DOI
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024. PubMed 38858523
Bench reconstitution
On the bench, dissolve the lyophilized cake in bacteriostatic water (0.9% benzyl alcohol) to the mg/mL your laboratory method specifies. Run solvent down the glass wall. Swirl gently until the cake is gone — do not vortex or shake. Record the resulting concentration, solvent lot, and time in the laboratory notebook.
Storage
Keep the lyophilized vial at 2–8 °C, protected from light and moisture, until bench use. After reconstitution, hold at 2–8 °C; use within the sterility window your laboratory controls allow. Do not freeze–thaw repeatedly. Record open date and concentration in the notebook.
Certificate of analysis
Every product has a View COA button. Where the lot certificate of analysis (identity and HPLC purity) is posted, it opens the certificate with a PDF download. Where it is not posted yet, the same button sends a request by email to request@pharmapeptidesrx.com, or you can write that address with the SKU. A catalog page is not a COA.
Lab procurement primer
A Canadian procurement primer for this compound — identifiers, selected literature, and lot COA — is in the retatrutide research primer. It contains no human-use guidance.
Lab FAQ
Is this catalog vial the NEJM trial product?
No. The 2023 phase 2 papers describe an investigational clinical product. The vial on this catalog is a research material for laboratory work. It is not authorized by Health Canada and is not a prescription drug.
In this library
In stock · list price
Request Retatrutide
Add vials to your request. We confirm stock and email the invoice at the listed price, or the volume price for 5 or more. Volume prices: 5–9 vials of one strength are 10% off each vial; 10 or more are 20% off. Standard shipping is $19.99 per order and free once the request reaches $250.00 before tax; expedited is $39.99. Sales tax follows the ship-to province and is included in the amount due. Labs pay by Interac e-Transfer. No card checkout.
$69.99CAD / vial